— Know what they know.
Not Investment Advice
Also trades as: 0K16.L (LSE) · $vol 0M

EOLS NASDAQ

Evolus, Inc.
1W: -10.4% 1M: -21.2% 3M: +2.1% YTD: +6.2% 1Y: +16.1% 3Y: -21.4% 5Y: -9.3%
$7.14
-0.55 (-7.15%)
 
Weekly Expected Move ±6.8%
$6 $7 $7 $8 $8
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 37 · $470.2M mcap · 50M float · 1.70% daily turnover · Short 67% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$470.2M
52W Range3.86-9.31
Volume2,070,849
Avg Volume848,781
Beta1.43
Dividend—
Analyst Ratings
11 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEODavid Moatazedi
Employees353
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2018-02-08
Websiteevolus.com
520 Newport Center Drive
Newport Beach, CA 92660
US
949 284 4555
About Evolus, Inc.

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Recent Insider Trades

NameTypeSharesPriceDate
MOATAZEDI DAVID S-Sale 105,108 $9.04 2026-09-02
Avelar Rui S-Sale 3,119 $4.75 2026-03-20
MOATAZEDI DAVID S-Sale 13,669 $4.75 2026-03-20
MOATAZEDI DAVID S-Sale 116,720 $4.89 2026-03-17
Avelar Rui S-Sale 29,996 $4.89 2026-03-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms